Volume 6 Supplement 3
P16-42. Characterisation of HIV-1 specific T-cell responses in exposed uninfected individuals from a London cohort
© Ritchie et al; licensee BioMed Central Ltd. 2009
Published: 22 October 2009
HIV-1 seronegative individuals exist who, despite repeated high-level exposure to HIV-1, fail to seroconvert. One explanation for this phenomenon is the existence of protective HIV-1 specific T-cell responses. In order to address this issue, we have established an MSM cohort at St Mary's STI clinic in London.
This cohort includes serodiscordant couples, consisting of one HIV positive and one exposed uninfected (EU) individual, and monogamous unexposed, uninfected (UU) couples. Strict criteria are used to enrol couples into these groups. The study is blinded and has been designed so that it has significant statistical power to detect whether there is a true difference in T cell responses between the EU and UU groups. Participants donate samples and answer a detailed sexual behaviour questionnaire (SBQ) during 4 visits, 3 months apart. PBMCs are isolated and used for ex vivo and highly-sensitvie cultured IFN-gamma ELISpot assays. In the cultured assay, antigen-specific T-cells populations are expanded and positive responses in EU and UU samples are further characterised to identify the individual peptide antigen recognised and whether responses are CD4 or CD8 restricted.
Enrolment for this study ceased in April, 2009, and initial T cell and SBQ analyses of all visit 1 data will be presented in this poster. Partial analysis of visit 1 showed T-cell responses in EU participants in 62% (8/13) cases and in UU participants in 32% (7/22) cases. Full analyses will include overall response rates, as well as whether specific responses are maintained longitudinally. Within the EU group, T cell responses are also being correlated with the presence of STIs, partner's viral load, and risk/exposure index.
Initial analysis suggests a difference in the rate of HIV-1 specific T-cell responses in EU and UU individuals, although full statistical analysis is on going.
Funded by NIAID Center for HIV/AIDS Vaccine Immunology grant AI067854.
This article is published under license to BioMed Central Ltd.